Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Alzheimer's Endpoint ADAS-Cog Likely Here To Stay Despite Clinical Failures

Oct 31 2016

• By Michael Cipriano

Neurons and nervous system. 3d render of nerve cells

Related Content

Efficacy Signal For Lilly’s Solanezumab Stirs The Alzheimer’s Pot

Oct 15 2012

Alzheon's Reclaimed Alzheimer's Drug Has Potential To Win Big – If History Doesn't Repeat

Oct 26 2016

Lundbeck’s STARSHINE Fades As Idalopirdine Fails First Phase III Alzheimer’s Test

Sep 23 2016

Related Companies

Pfizer Inc.

Alzheon Inc.

Eli Lilly and Company

Additional Topics

Clinical Trials Research & Development Drug Approval Standards Neurology BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window